Intellia Therapeutics Inc. (NASDAQ: NTLA) is 22.68% higher on its value in year-to-date trading and has touched a low of $9.18 and a high of $70.00 in the current 52-week trading range. The NTLA stock was last observed hovering at around $61.01 in the last trading session, with the day’s gains setting it 5.73% off its average median price target of $46.00 for the next 12 months. It is also 38.77% off the consensus price target high of $109.00 offered by 14 analysts, but current levels are -203.36% lower than the price target low of $22.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Currently trading at $66.74, the stock is 19.62% and 61.58% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.53 million and changing 9.39% at the moment leaves the stock 170.59% off its SMA200. NTLA registered 360.75% gain for a year compared to 6-month gain of 167.71%. The firm has a 50-day simple moving average (SMA 50) of $48.44 and a 200-day simple moving average (SMA200) of $28.65.
The stock witnessed a 53.64% loss in the last 1 month and extending the period to 3 months gives it a 217.66%, and is 22.19% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 10.52% over the week and 11.45% over the month.
Intellia Therapeutics Inc. (NTLA) has around 270 employees, a market worth around $4.10B and $62.30M in sales. Distance from 52-week low is 627.02% and -4.66% from its 52-week high.
Intellia Therapeutics Inc. (NTLA) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Intellia Therapeutics Inc. (NTLA) is a “Overweight”. 14 analysts offering their recommendations for the stock have an average rating of 2.20, where 5 rate it as a Hold and 1 think it is a “Overweight”. 8 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Intellia Therapeutics Inc. is expected to release its quarterly report on 05/04/2021 and quarterly earnings per share for the current quarter are estimated at -$0.61 with sales reaching $14.09M over the same period.The EPS is expected to shrink by -6.30% this year, but quarterly earnings will post 53.50% year-over-year. Quarterly sales are estimated to grow 28.80% in year-over-year returns.
Intellia Therapeutics Inc. (NTLA) Top Institutional Holders
249 institutions hold shares in Intellia Therapeutics Inc. (NTLA), with 8.02M shares held by insiders accounting for 13.58% while institutional investors hold 99.22% of the company’s shares. The shares outstanding are 58.75M, and float is at 49.25M with Short Float at 22.42%. Institutions hold 85.75% of the Float.
The top institutional shareholder in the company is ARK Investment Management, LLC with over 11.4 million shares valued at $226.73 million. The investor’s holdings represent 19.30% of the NTLA Shares outstanding. As of Sep 29, 2020, the second largest holder is Nikko Asset Management Americas, Inc. with 6.06 million shares valued at $120.52 million to account for 10.26% of the shares outstanding. The other top investors are Sumitomo Mitsui Trust Holdings, Inc. which holds 6.06 million shares representing 10.26% and valued at over $120.52 million, while Blackrock Inc. holds 9.55% of the shares totaling 5.65 million with a market value of $112.22 million.
Intellia Therapeutics Inc. (NTLA) Insider Activity
A total of 45 insider transactions have happened at Intellia Therapeutics Inc. (NTLA) in the last six months, with sales accounting for 24 and purchases happening 21 times. The most recent transaction is an insider sale by LEONARD JOHN M, the company’s President and CEO. SEC filings show that LEONARD JOHN M sold 6,239 shares of the company’s common stock on Jan 05 at a price of $55.86 per share for a total of $0.35 million. Following the sale, the insider now owns 0.48 million shares.
Intellia Therapeutics Inc. disclosed in a document filed with the SEC on Jan 05 that SCHIERMEIER ANDREW (EVP, Chief Operating Officer) sold a total of 1,377 shares of the company’s common stock. The trade occurred on Jan 05 and was made at $55.86 per share for $76919.0. Following the transaction, the insider now directly holds 16656.0 shares of the NTLA stock.
Still, SEC filings show that on Jan 05, Rivera Jose E (EVP, General Counsel) disposed off 2,078 shares at an average price of $55.86 for $0.12 million. The insider now directly holds 51,990 shares of Intellia Therapeutics Inc. (NTLA).
Intellia Therapeutics Inc. (NTLA): Who are the competitors?
The company’s main competitors (and peers) include Pieris Pharmaceuticals Inc. (PIRS) that is trading -19.23% down over the past 12 months. Short interest in the company’s stock has fallen -14.04% from the last report on Nov 12, 2020 to stand at a total of 12.59 million short shares sold with a short interest ratio of 7.69.